

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Edinger, et al.

SERIAL NUMBER:

09/997,594

EXAMINER:

Not Yet Assigned

FILING DATE:

November 29, 2001

ART UNIT:

FOR:

Endozepine-Like Proteins, Polynucleotides Encoding Them and Methods of Using

the Same

BOX IDS

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

A copy of each of the references in the above-identified application is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Attorney Docket No.: 21402-213 (Cura-513)

Exerces Mail Label No.: EV058074829US

2 5 2002 at of Deposit: February 25, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Edinger, et al.

SERIAL NUMBER:

09/997,594

EXAMINER: N

Not Yet Assigned

3,

FILING DATE:

November 29, 2001

ART UNIT:

FOR:

Endozepine-Like Proteins, Polynucleotides Encoding Them and Methods of Using

the Same

Box IDS

30623

DATENT TRAINCAARK OCCIO

Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (1 page) in duplicate;
- 3. Copies of cited references C1-19; and
- 3. Return Postcard

Dated: February 25, 2002

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 21402-213 (Cura-122). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elriff, Reg. No. 39,529

Attorney for Applicant

c/o MINTZ, LEVIN, COHN, FERRIS GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

APPLICANTS: U.S.S.N.:

Edinger, et al. 09/997,594

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-213.

Respectfully submitted,

Ivor R. Ehriff, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: February 25, 2002

TRA 1634194v1

	_
	•
1	

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO					Application Number		09/997,594			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					Filing Date		11/29/2001			
					First Named Inventor	r	Edinger			
					Group Art Unit					
					Examiner Name		Not Yet Assigned			
					Attorney Docket Numb	per	21402-213			
				U.S	. PATENT DOCUMENTS					
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name	of Patentee(s) or Applican	t(s)	Class	Sub Class	Filing Date If Appropriate	
				FORE	GN PATENT DOCUMENT	s				
Exam Initials	Cite No.	Foreign Patent Document Name			of Patentee(s) or Applicant	(s)			Translation Yes No	
			THER PRIOR	R ART -	NON PATENT LITERATU	RE DOCUMEN	NTS			
Exam Initials	Cite No.	Name of Author Title (when appropriate) Bublication Volume Base(s) Date Ste								
C1 Alderborn, et al. (2000). <i>Genome Res</i> <u>10(8)</u> : 1249-58.										
	C2	C3 Barbaccia, et al. (1986). Arch Gen Psychiatry 43(12): 1143-7. C4 de Mateos-Verchere, et al. (2001). Eur J Pharmacol 414(2-3): 225-31. C5 Edgar, et al. (1999). Mol Psychiatry 4(2): 173-8. C6 GenBank Accession Number: CAC24873 (22-JAN-2001) C7 GenBank Accession Number: CAC24877 (22-JAN-2001)								
	C3									
	C4									
	C5									
	C6									
	 									
C8 GenBank Accession Number: P07106 (16-OCT-2001) C9 Gooday, et al. (1995). <i>Psychopharmacology</i> (Berl) <u>119</u> (3): 295-8.										
C10 Gray, et al. (1986). Proc Natl Acad Sci U S A 83(19): 7547-5										
C11 Herzig, et al. (1996). Proc Natl Acad St C12 Ohkuma, et al. (2001). Life Sci 68(11):										
	C13	Rothstein, et al.	 -							
	C14				and 80(3): 287-91.					
	C15	Stepien, et al. (1	`							
	C16				cta 1454(1): 126-31.					
	C17				29CW41 (1-JUN-2001)					
	C18	SWALL (SPTR)	Accession Nu	ımber: C	9UFB5 (1-MAY-2000)					
	C19									
					previously cited by or su , and relied up and divisional application	_				
Examiner Signature					Date Considered					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.